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Abstract
Background: Randomised controlled trials are the gold standard for evaluating mental health care
interventions. We assessed the content and quality of trials published in Acta Psychiatrica
Scandinavica and Supplementum since 1948.
Methods: All trials were identified manually, quality assessed, data extracted, and sought on
Medline.
Results: About 8.6% of all reports in the journal were clinical trials (n = 582) with the peak
frequency in the 1980s. Most originate from Europe (80%) and focus on depression (~38%) or
schizophrenia (27%). The median sample size is 44. We found only two trials that fully met the
criteria of quality reporting RCTs set by CONSORT statements (0.34%) since 1996. Less than 50%
of records were possible to identify by a Medline search using broad methodological terms.
Conclusion: Acta is a major source of health trials. The standard of reporting is similar to other
journals but better adherence to CONSORT would ensure higher quality of reports and better
dissemination.
Background
Randomised trials are now widely accepted as the "gold
standard" for providing evidence on the effectiveness of
health care interventions in general [1] as well as mental
health care interventions in particular [2]. Random
assignment greatly reduces the potential for bias in the
allocation of interventions. It ensures that comparison
groups are as similar as possible to each other in terms of
both known and unknown possible predictors of treat-
ment response [3]. Empirical evidence suggests that non-
randomised studies tend to overestimate the effects of
healthcare [4]. In addition, the extent and the direction of
bias in these studies is often impossible to predict [5].
The use of randomised trials was largely restricted to eval-
uations of new drug therapies, either against an existing
standard agent or against a placebo control. More
recently, however, randomised controlled trials are being
used to evaluate a much broader range of interventions
[6].
Poorly conducted randomised trials, however, can pro-
vide biased results [7]. For example, allocation conceal-
ment, blinding, intention-to-treat analysis, and loss to
follow-up are the critical items in the design and conduct
of randomised trials, and an inadequately conceived, con-
ducted and reported randomised trial may overestimate
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order to improve design, conduct and reporting of trials
CONSORT guidance was drawn up first in 1996 [10] and
updated in 2001 [11].
Acta Psychiatrica Scandinavica is one of the leading psy-
chiatric journals with impact factor 3.857 (2006) [12],
since the first report of a randomised trial being used in
clinical medicine was published in 1948 [13], we aimed
to assess the content and quality of trials published Acta
Psychiatrica Scandinavica and Acta Psychiatrica Scandi-
navica Supplementum from 1948 to 2006.
Methods
All randomised controlled trials or controlled clinical tri-
als were identified by manually searching every page of all
relevant volumes of Acta Psychiatrica Scandinavica and
Acta Psychiatrica Scandinavica Supplementum from 1948
to Issue 4 of 2006, including Acta Psychiatrica et Neuro-
logica (1948–1950) and Acta Psychiatrica et Neurologica
Scandinavica (1951–1961) as Acta predecessors. Working
independently, HEM, MQA, and MOA used a standard-
ised data collection sheet to extract information from the
papers. Any disagreements were resolved by discussion.
We recorded year of publication, type of report, country of
origin (address of first author); characteristics of partici-
pants including diagnosis, sex, age (adults, elderly or chil-
dren), setting (hospital or community); variables
reporting trial design such as description of randomisa-
tion, size, presence of power calculation, consent, dura-
tion, parallel or crossover, type of intervention
(pharmacological or non-pharmacological) and out-
comes.
As allocation concealment is pivotal when describing the
likelihood of inclusion of over estimates of effect in trials
[14] this was assessed using the Cochrane Collaboration
criteria[15]. These criteria consider allocation conceal-
ment as 'adequate' when papers report sequentially
labelled, sealed, opaque envelopes or central or pharmacy
randomisation. By the same criteria, allocation conceal-
ment is 'unclear' when papers report randomisation
methods used in terms such as "patients were randomised
to..." or "treatment was assigned in random order..."
Finally, when methods of allocation were explicitly not at
random, or by alternation, number of medical record, or
date of birth, we categorised these as 'inadequate' ran-
domisation. In addition, each included trial was rated
using Jadad scale [16]. This measures a wider range of fac-
tors that impact on trial quality. Not only is randomisa-
tion rated (adequate = 2, unclear = 1, inadequate = 0), but
also double-blindness (adequate = 2, unclear = 1, inade-
quate = 0) and description of withdrawals (Yes = 1, No =
0). These particular data relevant to quality were chosen
because the Jadad rating, in particular, has been validated
for mental health trials, and because poor quality scores
are associated with over-estimates of effects of treatment
[4,8].
We also calculated the proportion of follow up by divid-
ing the number of participants for whom the primary out-
come measure was obtained and by the total number
randomised. Finally we recorded source of funding of tri-
als (pharmaceutical companies or not) and whether
authors were employed by these sources. Electronic
records of relevant records on the National Library of
Medicine's Medline database, on the PubMed platform,
were downloaded into reference manger software (ProC-
ite). We searched for the methodological indexing of all
records.
Statistical analysis
We calculated simple proportions. For trends over time,
we grouped data by decade and for this used SPSS (version
13, SPSS Inc., Chicago, IL, USA).
Results
Acta Psychiatrica Scandinavica and Acta Psychiatrica Scan-
dinavica Supplementum contain 582 reports of clinical
trials published between 1953 and 2006. According to
PubMed records, this is about 8.6% of all reports pub-
lished in the Journals since that time. Of these trials, most
(423, 73%) were randomised studies but 159 (27%) were
'controlled clinical trials'. In this type of study, randomi-
sation is implied rather than made explicit. Of the 582 tri-
als, most were published as original papers (560, 96%),
with only ten (1.7%) being abstracts alone. The remaining
12 (2.3%) were either conference proceedings or letters.
Reports by Region
The first trial appeared in 1953. Numbers then increased
until the 1980's and seemed to peak during that decade
(Figure 1). Over 80% (467) of reports of trials were first-
authored by someone from Europe, with 138 conducted
in Sweden, 69 in Denmark and 67 in the UK (Table 1).
Fifty reports (8.6%) originated form the USA. The first
Table 1: Reports by region
Region Number of reports of trials %
Europe 467 80.2
North America 63 10.8
Australia 10 1.7
South East Asia 10 1.7
Indian Subcontinent 4 0.7
Middle East 4 0.7
South America 4 0.7
Africa 2 0.3
Not reported 18 3.1
Total 582 100Page 2 of 5
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been a steady increase in the published trials originating
from there ever since. Thirty percent of studies were car-
ried out in community settings, over 50% in hospitals and
6% in both. For the remainder the setting was unclear.
Sample size and participants
Data on sample size were available for 577 trials. The
median sample size was 44 (IQR 24, 74) with a range [1,
705] and mode of 40. Of the 582 trials, only 11 (1.9%)
reported a power calculation. Participants in almost two
third of the trials (440 trials, 75%) were both men and
women and 546 trials (94%) were conducted on adults.
Participants in only seven trials (1.2%) were children and
in 29 (5%) were elderly. The diagnosis of trial participants
is shown in Table 2. Trials concerned with depression
account for nearly 38% of the total and schizophrenia and
'psychoses' studies, another 32%. Reports stated that con-
sent had been gained from participants in 225 trials
(39%). The form of the consent was either written or ver-
bal and it may have involved a legal guardian.
Trial methods
Most trials (459, 79%) were conducted using a parallel
group design, in which participants were allocated to a
particular intervention for the entire duration of the study
with crossover techniques used in the remainder (123,
21%). Reports stated that allocation to the various inter-
ventions was by "randomisation". Over 70% trials did not
report the explicit methods by which people were allo-
cated to interventions. Description of allocation conceal-
ment was rare (2.4%). We found only two trials that fully
met the criteria of quality reporting RCTs set by CON-
SORT statements (0.34%). Blinding of participants and
investigators (double blinding) was employed in 61% of
trials but clear descriptions of how this was undertaken
and monitored was only reported in 38 (6.5%). Com-
pleteness of follow-up was relatively high with over 75%
of trials having fewer than 20% participants lost to follow
up. Details of the reasons for leaving early were reported
in 344 trials (59%). When reporting of allocation, blind-
ing and loss to follow up are compiled into a Jadad score,
low scores, 2 or below, indicate poor quality and are asso-
ciated with over estimation of effects. Overall 353 (61%)
of studies in the Journals fell into this category. Propor-
tions of well-reported trials have changed over time (Table
3) but wide confidence intervals indicate that this
improvement has not reached statistical significance. The
impression of some improvement is paralleled by the
increasing impact of Acta [17].
Interventions and outcomes
Interventions were most commonly pharmaceutical
(Table 4) with only small proportions investigating the
effects of psychotherapies these studies being particularly
rare in depression. Outcomes were measured in many
ways but covered the broad categories expected in mental
health trials (global state 68%, adverse effects 51%, men-
tal state 20%). Measures or reports of satisfaction with
treatment were found in only six (1%) studies, cost elec-
tiveness, in four (0.7%) and quality of life, three (0.5%).
Most trials were of short duration, with 70 (12%) lasting
less than one week and 260 (45%) between one and six
weeks. 26% (152) lasted over six weeks to six months, but
only 63 (11%) were longer than those periods (37, 6%
not reported).
Source of funding
Trials reported source of funding 183 trials (31.5%) with
pharmaceutical companies supporting 82 (45%) and the
remaining 101 trials funded by national medical research
counsels and academic institutes. Principal investigators
in 21/183 trials were directly employed by those provid-
ing funding.
Number of reports of trials by year of publicationFigur  1
Number of reports of trials by year of publication.
Table 2: Diagnosis of trial participants
Diagnosis Number of reports of trials %
Depression 218 37.5
Schizophrenia 157 27
Healthy Volunteer 48 8.2
Neurotic Disorder 44 7.6
Psychosis 30 5.2
Cognitive Disorder 19 3.3
Sleep Disorder 17 2.9
Addiction Problem 14 2.4
Affective disorder 14 2.4
Organic Disorders 11 1.9
Personality Disorder 10 1.7
Total 582 100Page 3 of 5
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By searching Medline and Old Medline, we found 566
records for the 582 trials (97.3%). The National Library
(NLM), who index for Medline, do not, by policy, index
conference abstracts and indexing of letters is somewhat
haphazard [18] and it is for this reason that 2.7% of stud-
ies in the Actas are not in Medline or Old Medline. Search-
ing the indexing terms by the simple phrase "RANDOM*"
identified only 54 records (9.3%). Expanding this to
"RANDOM* OR (DOUBLE-BLIND* or (DOUBL* AND
BLIND*))" still only identified 273 records (47%).
Searching both NLM index terms combined with free text
(including abstract and title) by "RANDOM*" identified
237 records (41%) and the "RANDOM* OR (DOUBLE-
BLIND* or (DOUBL* AND BLIND*))" phrase 396
records (68%).
Discussion
This study shows how Acta Psychiatrica Scandinavica and
Acta Psychiatrica Scandinavica Supplementum have pub-
lished a wide range of trials over the last five decades. The
proportion of all studies that were RCTs or CCTs (8.6%)
being very similar to that in other specialties (8.4%) [19].
Most trials in these European journals originated from
Europe. This 'home advantage' has also been demon-
strated for other journals [20] but it is encouraging that
the proportion of trials from outside Europe in Acta is
increasing. We are unclear why the number of trials in the
journals seems to be decreasing across time. This may be
that studies are being published elsewhere. There is an
ever-increasing number of journals vying for authors,
Acta's editorial policy or the attractiveness of the journals
could have changed over time – for example, by decreas-
ing impact factor. Certainly, other information suggests
that there are not fewer mental health trials being pub-
lished over the same period [20-22].
The content and quality of trials in Acta Psychiatrica Scan-
dinavica and Acta Psychiatrica Scandinavica Supplemen-
tum seems similar to those in other major sources [21,22].
Most studies are small (only 1.9% even reported under-
taking a power calculation), short (>50% 6 weeks or less)
and problematic to apply to everyday care. Moreover, they
are so poorly reported that readers have to be concerned
as to the validity of their findings. From Table 3 it can be
seen that a reasonably high proportion of trials do fall
into the 'good quality' category and the impression of
improvement (too underpowered to clearly show a statis-
tically significant incline) is paralleled by increasing
impact of Acta. This proportion of 'good quality' studies is
more than has been seen in preceding similar work
[20,21]. However, over 60% of trials continue to have
minimal reporting of methods and this is associated with
exaggerated estimates of effect [4,8].
We implemented the Jadad scale as it is the only scale that
has been developed using established standards for scales
and where low scores have been associated with increased
effect estimates [23]. However, despite its thorough devel-
opment and validation, the scale has more focus on the
quality of reporting than on methodological quality [24].
As for randomisation, the scale addresses the sequence
generation but not concealment of allocation as even ade-
quate concealment of allocation may not prevent against
selection bias if the sequence generation is deciphered by
the persons enrolling patients [23].
In undertaking a survey of this kind there is a danger of
judging work from decades ago by standards of today.
However, when this has been applied to other mental
health journals findings have been surprising with, for
example, the quality of reporting in one major journal
declining across time [21]. The CONSORT statement,
published over a decade ago, does not seem to have been
incorporated into Acta's reporting style.
The indexing of randomised studies could also be
improved. Just less than 70% are identified by a broad
methodology search in Medline. Even though 123 records
did use the terms 'randomised' or 'randomly assigned/
allocated' or 'double blind' in the title or abstract of the
work, these were not indexed as such by The National
Library of Medicine. Medline and Old Medline indexing
contains much [understandable] human error. There is,
however, a suggestion that 32% of randomised or control-
led clinical trials did not mention a methodological term
in an obvious way so as to allow easy indexing. It is
encouraging that this proportion as steadily decreased
across time (95% 1960's, 48% 1970's, 24% 1980's, 16%
1990's), but that 10% of randomised trials since the year
2000 still do not mention key methodological terms in
the title or abstract is not good and could be improved by
editorial policy. In this way both trialists and editors
could be more assured that valuable studies in Acta Psy-
chiatrica Scandinavica and Acta Psychiatrica Scandinavica
Supplementum will be identified, used, cited and contrib-
ute to impact.
Table 3: Jadad score by time and impact factor
Jadad score
0–2 3–5 (good quality)
Impact factor N N % 95% CI
1950s - 7 0 - -
1960s - 16 5 23.8 11–45
1970s - 91 59 39.3 32–47
1980s - 149 97 39.4 34–46
1990s 1.3–1.7 70 56 44.4 36–53
2000–6 1.7–2.4 20 12 37.5 23–55
Totals 353 229 39.3 35–43Page 4 of 5
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Acta Psychiatrica Scandinavica and Acta Psychiatrica Scan-
dinavica Supplementum are major sources of mental
health trials undertaken in the last half century. The small
but increasing proportion of trials from outside of Europe
is encouraging, although why the number of trials in the
journals is declining is not clear. The standard of reporting
is as high, if not higher in these journals compared with
their competitors – but could improve with little addi-
tional effort. Better adherence to CONSORT would ensure
higher quality of reports, better indexing and, as a conse-
quence, wider dissemination.
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